955028-75-8

Basic information

• Product Name: tert-butyl (3S,4S)-rel-3-hydroxy-4-methylpiperidine-1-carboxylate
• Synonyms: tert-butyl (3S,4S)-rel-3-hydroxy-4-methylpiperidine-1-carboxylate;Cis-Tert-Butyl 3-Hydroxy-4-Methylpiperidine-1-Carboxylate;Cis-Tert-Butyl 3-Hydroxy-4-Methylpiperidine-1-Carboxylate(WX642014)
• CAS NO: 955028-75-8
• Molecular Formula: C11H21NO3
• Molecular Weight: 215.29
• Mol File: 955028-75-8.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 301.4±35.0 °C(Predicted)
• Appearance: /
• Density: 1.067±0.06 g/cm3(Predicted)
• PKA: 14.76±0.40(Predicted)
• CAS DataBase Reference: tert-butyl (3S,4S)-rel-3-hydroxy-4-methylpiperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (3S,4S)-rel-3-hydroxy-4-methylpiperidine-1-carboxylate(955028-75-8)
• EPA Substance Registry System: tert-butyl (3S,4S)-rel-3-hydroxy-4-methylpiperidine-1-carboxylate(955028-75-8)

Safety Data

• Hazardous Substances Data: 955028-75-8(Hazardous Substances Data)

Usage

General Description

Tert-butyl (3S,4S)-rel-3-hydroxy-4-methylpiperidine-1-carboxylate is a chemical compound with the molecular formula C12H23NO3. It is a synthetic derivative of piperidine and is commonly used in the pharmaceutical industry as a building block for the synthesis of various drugs. tert-butyl (3S,4S)-rel-3-hydroxy-4-methylpiperidine-1-carboxylate has a tert-butyl group attached to the nitrogen atom of the piperidine ring, as well as a hydroxyl group and a methyl group at the 3 and 4 positions, respectively. The stereochemistry of the molecule is specified as (3S,4S)-rel, indicating the configuration of the substituents on the chiral centers. Tert-butyl (3S,4S)-rel-3-hydroxy-4-methylpiperidine-1-carboxylate is an important intermediate in the synthesis of pharmacologically active compounds and plays a crucial role in drug discovery and development.

Upstream product

• 374794-74-8 (trans)-3-hydroxy-4-methyl-piperidine hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 81474-43-3 (4R,5S)-5-(hydroxymethyl)-4-methyldihydrofuran-2(3H)-one 
• 88424-25-3 methyl (±)-(3-oxiran-2-yl)butanoate 
• 65371-40-6 trans-γ-iodomethyl-β-methyl-γ-butyrolactone 
• 75371-78-7 3-methyl-pent-4-enoic acid 
• 374822-48-7 C₆H₁₃NO 
• 179685-91-7 (4S,5S)-5-azidomethyl-4-methyl-4,5-dihydro-2(3H)-furanone 
• 1188264-78-9 rac-tert-butyl (3S,4R)-3-hydroxy-4-methylpiperidine-1-carboxylate 
• 384338-20-9 (rac, trans)-1-benzyl-4-methyl-piperidin-3-ol 
• 374822-48-7 C₆H₁₃NO 
• 1188264-78-9 (rac, cis)-3-hydroxy-4-methyl-piperidine-1-carboxylic acid tert-butyl ester 
• 176966-79-3 (4R,5S)-5-(tert-Butyl-diphenyl-silanyloxy)-4-methyl-2-oxo-piperidine-1-carboxylic acid tert-butyl ester 
• 176966-80-6 tert-butyl (5S)-5-(tert-butyldiphenylsilyloxy)-4-methyl-2H-2-oxo-5,6-dihydro-piperidine-1-carboxylate 

Relevant articles and documents

Synthesis of key intermediate for (+)-tofacitinib through CoIII(salen)-catalyzed two stereocentered hydrolytic kinetic resolution of (±)-methyl-3-(oxiran-2-yl)butanoate

An enantiopure piperidine, a key intermediate for the synthesis of (+)-tofacitinib, has been achieved in high optical purity (98% ee) from readily available crotyl alcohol. The key steps involved is a CoIII(salen)-OAc-catalyzed two stereocentered hydrolytic kinetic resolution of (±)-methyl-3-(oxiran-2-yl)butanoate.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel bicyclic compounds of formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9, and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor may be used, for example, in the prevention and/or treatment of inflammatory diseases, particularly peripheral arterial occlusive diseases or atherothrombosis.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y1, Y2, Y3, R3, R4, R5, R6, R7, R8, R9, R10, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.